CanaQuest Medical Corp. announced it was awarded a European Cannabinoid Patent, a novel Botanical and Tetrahydrocannabinol ("THC") Formulation for the reduction of cannabis-induced negative neuropsychiatric side-effects. The formulated product is branded as Mentabinol®?, which addresses various psychiatric disorders.

Acute THC consumption can trigger worrying thoughts in vulnerable individuals. Mentabinol®? - Formulation utilizing pharmaceutical-grade botanical extract, L-theanine, and THC molecules extracted from cannabis.

The Scientific Difference - based on pre-clinical trial results at Western University. For many users, THC causes: Memory impairment and possible long-term cognitive side effects, Depression-like and schizophrenia-related symptoms, Anxiety and hyperactive activity, Schizophrenia due to gene vulnerability. Application of Mentabinol®?

has demonstrated in pre-clinical trials: Reversal of depression-like and schizophrenia-related symptom effects, Blockage of memory impairment, hyperactive activity, and gene vulnerability. The discovery was made by a research team led by Dr. Steven Laviolette, a professor, and neuroscientist at Western University with decades of experience in the fields of mental health and cannabinoids. Western University researchers believe this formulation may mitigate this type of harm to chronic cannabis users.

The team also concluded that their research provides evidence for combining the THC-based formulations with L-theanine to make them safer for both recreational and medicinal use. Physicians, psychiatrists, and healthcare practitioners, interested in joining network, as well as institutions, clinics, and pharmacies, can register via Join network.